Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2628359
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Level1 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 24 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div. day1,8 U3-1565: 16 mg/kg div day1 q2w Level0 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 16 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div day1,8 U3-1565: 12 mg/kg div day1,8 q2w
Primary outcome(s): Proportion of DLT(Dose limiting toxicity)
Study Design: Single arm Non-randomized
创建时间：
2014-03-15
